Cui Jianyi, Gong Rui, Hu Shuiqing, Cai Ling, Chen Lei
Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, People's Republic of China.
Department of Ophthalmology, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, Liaoning, People's Republic of China.
Life Sci. 2018 Jan 1;192:293-303. doi: 10.1016/j.lfs.2017.11.007. Epub 2017 Nov 10.
Gambogic acid (GA) is one of active components of Chinese medicine gamboges resin. Diabetic retinopathy (DR) is a most serious microvascular complication of diabetes and also the leading cause of blindness. The aim of this study is to evaluate the beneficial effect of GA on diabetes-induced retinal angiogenesis and further explore the potential mechanisms.
High glucose (HG)-treated RF/6A cells and STZ-induced diabetic mice were used as in vitro and in vivo models. Then the effects of GA on proliferation, migration and tube formation in RF/6A cells and pathomorphological changes in STZ-induced diabetic mice were determined. The activation of HIF-1α/VEGF and PI3K/AKT signaling pathways was assessed by various molecular biological experiments.
According to our results, GA inhibited HG-induced proliferation, migration and tube formation in choroid-retinal endothelial RF/6A cells. The upregulation of HIF-1α and VEGF induced by HG in RF/6A cells was restrained by GA treatment significantly. Moreover, GA suppressed retinal pathomorphological changes and angiogenesis in STZ-induced diabetic mice in vivo, and also inhibited the activation of HIF-1α/VEGF pathway induced by diabetics. Finally, GA suppressed the activation of PI3K/AKT signaling pathway in STZ-induced diabetic mice in vivo and in HG-induced RF/6A cells in vitro. Further activation of PI3K/AKT pathway by IGF-1 restrained the beneficial effect of GA in RF/6A cells.
Our results provide evidence that GA may ameliorate diabetes-induced retinal angiogenesis, which are proofs that GA may be developed as a potential drug for treating DR.
藤黄酸(GA)是中药藤黄树脂的活性成分之一。糖尿病视网膜病变(DR)是糖尿病最严重的微血管并发症,也是失明的主要原因。本研究旨在评估GA对糖尿病诱导的视网膜血管生成的有益作用,并进一步探讨其潜在机制。
将高糖(HG)处理的RF/6A细胞和链脲佐菌素诱导的糖尿病小鼠作为体外和体内模型。然后测定GA对RF/6A细胞增殖、迁移和管腔形成的影响以及对链脲佐菌素诱导的糖尿病小鼠的病理形态学变化。通过各种分子生物学实验评估HIF-1α/VEGF和PI3K/AKT信号通路的激活情况。
根据我们的结果,GA抑制了HG诱导的脉络膜视网膜内皮RF/6A细胞的增殖、迁移和管腔形成。GA处理显著抑制了HG诱导的RF/6A细胞中HIF-1α和VEGF的上调。此外,GA在体内抑制了链脲佐菌素诱导的糖尿病小鼠的视网膜病理形态学变化和血管生成,并且还抑制了糖尿病诱导的HIF-1α/VEGF通路的激活。最后,GA在体内抑制了链脲佐菌素诱导的糖尿病小鼠以及体外HG诱导的RF/6A细胞中PI3K/AKT信号通路的激活。IGF-1对PI3K/AKT通路的进一步激活抑制了GA在RF/6A细胞中的有益作用。
我们的结果提供了证据表明GA可能改善糖尿病诱导的视网膜血管生成,这证明GA可能被开发成为一种治疗DR的潜在药物。